

P755

The impact of levothyroxine on cardiac function in older adults with subclinical hypothyroidism: a randomized clinical trial

B. Gencer¹, E. Moutzouri², M.R. Blum³, M. Feller², T.H. Collet⁴, E. Buffle⁵, P. Monney⁶, V. Gabus⁶, H. Muller¹, P. Kearney⁷, J. Gussekloo⁸, R. Westendorp⁹, D.J. Scott¹⁰, D.C. Bauer¹¹, N. Rodondi³

¹Geneva University Hospitals, Cardiology Division, Geneva, Switzerland; ²University of Bern, Institute of Primary Health Care (BIHAM), Bern, Switzerland; ³Bern University Hospital, Department of General Internal Medicine, Bern, Switzerland; ⁴University Hospital Centre Vaudois (CHUV), Service of Endocrinology, Diabetes and Metabolism, Lausanne, Switzerland; ⁵Bern University Hospital, Department of Cardiology, Bern, Switzerland; ⁶University Hospital Centre Vaudois (CHUV), Service of Cardiology, Department of Heart and Vessels, Lausanne, Switzerland; ⁷University College Cork, Cork, Ireland; ⁸Leiden University Medical Center, Leiden, Netherlands (The); ⁹University of Copenhagen, Center for Healthy Aging, Copenhagen, Denmark; ¹⁰University of Glasgow, Institute of Cardiovascular and Medical Sciences, Glasgow, United Kingdom; ¹¹University of California San Francisco, San Francisco, United States of America

Importance: Subclinical hypothyroidism has been associated with heart failure, but no conclusive clinical trial assessed whether treating subclinical hypothyroidism with levothyroxine has an impact on cardiac function.

Objective: To assess the impact of levothyroxine treatment on cardiac function in subclinical hypothyroidism.

Design: This is a randomized, double-blind placebo-controlled, multicenter Swiss substudy within the TRUST trial.

Participants: Participants aged ≥ 65 years with subclinical hypothyroidism.

Intervention: Levothyroxine to achieve TSH normalization, or placebo including mock titrations.

Main outcome measures: Primary outcomes, assessed by echocardiography at the end of the trial were the left ventricular ejection fraction (LVEF, normal defined as $> 50\%$) for systolic function and the ratio between mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (e') (E/e' ratio) for diastolic function. Secondary outcomes included transmitral E and A waves, e' lateral/septal, left atrial (LA) volume index and systolic pulmonary artery pressure.

Results: Of 217 randomized Swiss participants of the TRUST trial, 185

(mean age 74.1 years, 47% women, mean TSH at baseline $6.35 \pm \text{SD } 1.95$ mIU/L) underwent echocardiography. After a median treatment duration of 18.4 months, the mean TSH among participants randomized to levothyroxine (n=95) decreased to 3.55 mIU/L, whereas it remained elevated in the placebo group (n=89; 5.29 mIU/L). The mean LVEF was similar in both arms (adjusted between-group difference 0.4%, 95% CI -1.8% to 2.5% , $P=0.72$) and no significant differences were found for the E/e' ratio (adjusted between-group difference 0.4, 95% CI -0.7 to 1.4 , $P=0.47$). In intention-to-treat and per-protocol analyses, no clinically significant differences were found for secondary diastolic function parameters: e' lateral 8 vs. 8 cm/s, $P=0.54$; e' septal 6 vs. 6 cm/s, $P=0.75$; LA volume index 34 vs. 33 ml/m², $P=0.57$; E/A ratio 0.8 vs. 0.8, $P=0.94$; E deceleration time 225 vs. 216 ms, $P=0.27$, except for systolic pulmonary artery pressure (37 mm Hg in the levothyroxine group vs. 33 mm Hg in the placebo group, $P=0.02$ intention-to-treat and $P=0.06$ per protocol)

Conclusion: Treatment of subclinical hypothyroidism with levothyroxine was not associated with benefits regarding systolic and diastolic heart function in older adults with subclinical hypothyroidism.